Nanjing Edgar Biopharmaceutical Technology

Nanjing Edgar Biopharmaceutical Technology is a clinical-stage biotechnology company based in Nanjing, China, focused on the discovery and development of innovative small molecule therapeutics. Founded in 2017, the company primarily targets unmet medical needs in oncology and autoimmune diseases through its proprietary drug discovery platform. Its lead program, EDG-001, is a highly selective RET inhibitor currently undergoing Phase 1 clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer. The company leverages structure-based drug design and advanced medicinal chemistry to develop candidates with superior potency and selectivity. Edgar Biopharmaceutical is headquartered in the Nanjing Jiangbei New Area, benefiting from the region's robust life sciences ecosystem and government support. The firm aims to provide high-quality, affordable precision medicines to patients globally by bridging the gap between innovative research and clinical application.